TG Therapeutics Inc
Company Profile
Business description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Contact
3020 Carrington Mill Boulevard
Suite 475
MorrisvilleNC27560
USAT: +1 212 554-4484
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
352
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,756.60 | 39.40 | -0.45% |
| CAC 40 | 7,765.11 | 10.79 | -0.14% |
| DAX 40 | 23,771.45 | 177.45 | -0.74% |
| Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
| FTSE 100 | 8,884.92 | 20.57 | 0.23% |
| HKSE | 23,866.86 | 168.52 | -0.70% |
| NASDAQ | 19,662.48 | 46.61 | 0.24% |
| Nikkei 225 | 37,689.16 | 483.93 | -1.27% |
| NZX 50 Index | 12,526.07 | 123.03 | -0.97% |
| S&P 500 | 6,045.26 | 23.02 | 0.38% |
| S&P/ASX 200 | 8,533.90 | 31.20 | -0.36% |
| SSE Composite Index | 3,378.01 | 24.64 | -0.72% |